Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17OWWlEPTB;MD6wNFA1PThibl2= NWr1UlhjW0GQR1XS
ES4 NHfCVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMECwOlU{KG6P MljEV2FPT0WU
ACHN M2C1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTKTWM2OD1yLkCwNFg5PyCwTR?= NED3O5lUSU6JRWK=
KYSE-510 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HmO2lEPTB;MD6wNFA6PzVibl2= MUfTRW5ITVJ?
EW-7 NYj4[VdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn20TWM2OD1yLkCwNlU5KG6P NVTNdlhoW0GQR1XS
BFTC-905 M3rodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTTTWM2OD1yLkCwOVE2KG6P NHPpOWZUSU6JRWK=
KE-37 NYLOR4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PBd2lEPTB;MD6wNFU3OSCwTR?= NV3Te3NTW0GQR1XS
SBC-5 NEPCboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LwSGlEPTB;MD6wNFU4KG6P MXrTRW5ITVJ?
NKM-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjpV2ZKSzVyPUCuNFA4ODlibl2= NIrHZY1USU6JRWK=
RH-1 M2rHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLtNpdWUUN3ME2wMlAxPzF6IH7N NIPuUGVUSU6JRWK=
ALL-PO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMEC4N{BvVQ>? MojJV2FPT0WU
QIMR-WIL M2jtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEC4PVQhdk1? NVHXemRlW0GQR1XS
A375 M2W0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:4TWM2OD1yLkCwPVk2KG6P M1jLTnNCVkeHUh?=
SIG-M5 NUPIOYpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX6[WhKSzVyPUCuNFExPCCwTR?= MYjTRW5ITVJ?
KGN MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEGwPEBvVQ>? M2e5RnNCVkeHUh?=
EW-13 NFTPWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfubnVDUUN3ME2wMlAyOTJibl2= MVXTRW5ITVJ?
NCI-SNU-1 NWD1TG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnNPGRKSzVyPUCuNFE3KG6P NYPoUYM1W0GQR1XS
PSN1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0bGlEPTB;MD6wNVY2KG6P MVPTRW5ITVJ?
HUTU-80 NYjRVoZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH31UGtKSzVyPUCuNFE3PiCwTR?= NUT6R49lW0GQR1XS
EW-16 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGzZmFzUUN3ME2wMlAzOyCwTR?= NYPBS4pPW0GQR1XS
786-0 NHLIeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjiTIJxUUN3ME2wMlAzOyCwTR?= MVHTRW5ITVJ?
ES1 MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPLWXB2UUN3ME2wMlAzPjhibl2= MYDTRW5ITVJ?
RKO MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEK3PUBvVQ>? NUnMbYxOW0GQR1XS
ESS-1 NYHid2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXFTmhKSzVyPUCuNFI5PiCwTR?= NYDGUWZWW0GQR1XS
SK-UT-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLmPJJKSzVyPUCuNFI6PyCwTR?= NFqzdnZUSU6JRWK=
LB2241-RCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\vTWM2OD1yLkCzNVghdk1? MlzuV2FPT0WU
CHL-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LIfGlEPTB;MD6wN|I1KG6P M4[4Z3NCVkeHUh?=
SW1783 NYjzb3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\6OGlEPTB;MD6wN|M3KG6P MlHEV2FPT0WU
MEL-JUSO NUXGdFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rHPWlEPTB;MD6wN|kyKG6P NUXQZoF3W0GQR1XS
HT-29 MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrmbIJjUUN3ME2wMlA1OTNibl2= M164VHNCVkeHUh?=
SNG-M NIjEXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe3PVJKSzVyPUCuNFQzPSCwTR?= NYnSeHNRW0GQR1XS
TE-15 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMES2OEBvVQ>? NF;wbpNUSU6JRWK=
HOS Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPYTWM2OD1yLkC0PEBvVQ>? NHjHcZZUSU6JRWK=
BB65-RCC NFLSPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULXNmw4UUN3ME2wMlA2OTJibl2= NFvwSJdUSU6JRWK=
HCE-4 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PYS2lEPTB;MD6wOVI5KG6P NYfocpUzW0GQR1XS
MHH-ES-1 M2[4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG0TWM2OD1yLkC1N|Ehdk1? NUPBNFNYW0GQR1XS
RPMI-7951 M3T1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEW0NUBvVQ>? NGGzXZhUSU6JRWK=
IST-SL2 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD1yLkC1PFQhdk1? NH;UXGJUSU6JRWK=
CMK NULmTWtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX5TWM2OD1yLkC1PFYhdk1? NV3YSG1WW0GQR1XS
GR-ST M1\Jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjlS3BTUUN3ME2wMlA2QTVibl2= Mne3V2FPT0WU
NALM-6 NVnwTI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLoTYtKSzVyPUCuNFYzOiCwTR?= Mle5V2FPT0WU
RPMI-6666 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX22dWNOUUN3ME2wMlA3PTJibl2= MmWwV2FPT0WU
LC-2-ad M{C2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml72TWM2OD1yLkC2OVMhdk1? NXnFUHpEW0GQR1XS
ARH-77 NX\SXXBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEexNUBvVQ>? M1PBU3NCVkeHUh?=
IST-MEL1 NVjwN5BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7UTWM2OD1yLkC3NlYhdk1? M1;CenNCVkeHUh?=
SW1710 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjrTWM2OD1yLkC3OVEhdk1? MoDnV2FPT0WU
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEi4O{BvVQ>? MlPoV2FPT0WU
AGS NF7KPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEmwNkBvVQ>? Mn7tV2FPT0WU
NCI-H2122 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\3fYJwUUN3ME2wMlA6PDZibl2= M{fCNnNCVkeHUh?=
HSC-4 M2\Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n0PGlEPTB;MD6xNFIhdk1? MmLhV2FPT0WU
AM-38 M13NcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVntXVBlUUN3ME2wMlEzOSCwTR?= NYmxNGdWW0GQR1XS
769-P MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLCeItKSzVyPUCuNVI{KG6P MWLTRW5ITVJ?
RT-112 NGDSU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMUK3JI5O NXvvb2NWW0GQR1XS
MCF7 NEL4XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjuTWM2OD1yLkGzOkBvVQ>? NIOzN2dUSU6JRWK=
IGROV-1 NXPtRZI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3pTWM2OD1yLkG0OUBvVQ>? MWfTRW5ITVJ?
OCI-AML2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPsWY9KSzVyPUCuNVQ4KG6P M2\yTHNCVkeHUh?=
NCI-H1299 NWLVXnF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMUW3JI5O M1fnXXNCVkeHUh?=
A431 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXQRWpKSzVyPUCuNVg{KG6P Ml7jV2FPT0WU
SW982 NWjhWmhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMkGzJI5O M2WxW3NCVkeHUh?=
BB30-HNC Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfjUVJsUUN3ME2wMlI{OSCwTR?= M2r1eHNCVkeHUh?=
ACN MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzscoxRUUN3ME2wMlI1PCCwTR?= MUjTRW5ITVJ?
647-V MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH72UVBKSzVyPUCuNlQ5KG6P Ml7jV2FPT0WU
SK-PN-DW M2O5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXGc2RKSzVyPUCuNlY3KG6P MUjTRW5ITVJ?
LCLC-97TM1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml30TWM2OD1yLkK2O{BvVQ>? MXPTRW5ITVJ?
LB1047-RCC MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDTe2RLUUN3ME2wMlI3QSCwTR?= M3q3fnNCVkeHUh?=
A2780 M2\rRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMR2lEPTB;MD6yO{BvVQ>? MVvTRW5ITVJ?
C-33-A MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjyfZpKSzVyPUCuNlc{KG6P M4nPdHNCVkeHUh?=
NCI-H2228 NXjiVFBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz3cotQUUN3ME2wMlMyPCCwTR?= NHHPc|RUSU6JRWK=
TE-5 NF2yPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17VOmlEPTB;MD6zNVYhdk1? NV\kUWVGW0GQR1XS
HC-1 NX33SJpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[xTWM2OD1yLkOyO{BvVQ>? MkLJV2FPT0WU
SK-MES-1 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPD[o0xUUN3ME2wMlMzQCCwTR?= M2PvW3NCVkeHUh?=
NCI-H1355 M3XDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOzZ2hKSzVyPUCuN|gyKG6P MknjV2FPT0WU
YKG-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M132XmlEPTB;MD60NVkhdk1? MkTLV2FPT0WU
RS4-11 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNEOzJI5O MlPBV2FPT0WU
Daoy NVf1fG5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[wTWM2OD1yLkS1OkBvVQ>? NIfC[lhUSU6JRWK=
A3-KAW M2XjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HXNWlEPTB;MD61OVEhdk1? M4HxeXNCVkeHUh?=
SK-MEL-30 NWCyWYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwNUW0JI5O M1HzNnNCVkeHUh?=
U031 M{\PZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[wTWM2OD1yLkW2OUBvVQ>? NVPBXJB[W0GQR1XS
SK-LMS-1 NGDkTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLQTWM2OD1yLkW3PEBvVQ>? MUTTRW5ITVJ?
ES6 M1LGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\udGlEPTB;MD61PFYhdk1? MlvMV2FPT0WU
EoL-1-cell M4n6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\GTWM2OD1yLk[xOkBvVQ>? MVrTRW5ITVJ?
NCI-H2009 M3nRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz3[lZKSzVyPUCuOlE6KG6P M1XLfXNCVkeHUh?=
A4-Fuk NV6wbppGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvOTWM2OD1yLk[yOkBvVQ>? NXTVWnUyW0GQR1XS
KYSE-270 NIPYSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LONmlEPTB;MD62N|Qhdk1? MnnxV2FPT0WU
SK-LU-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzTTWM2OD1yLk[1OUBvVQ>? MnvkV2FPT0WU
SW872 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwN{[1JI5O MmrLV2FPT0WU
ES8 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwN{igcm0> MmXHV2FPT0WU
G-402 NES5T3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPVb5BKSzVyPUCuO|g1KG6P NUnNUlBQW0GQR1XS
ATN-1 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzFTWM2OD1yLkiwO{BvVQ>? M4e4cHNCVkeHUh?=
DoTc2-4510 M{W3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwOUCxJI5O NGfmfIZUSU6JRWK=
MES-SA M{DVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfBZlNKSzVyPUCuPVA2KG6P NXPzZ5ljW0GQR1XS
SF268 NUjxSHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G3V2lEPTB;MD65Nlchdk1? NXSwS|BMW0GQR1XS
SF539 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL2WYZKSzVyPUGuNFIhdk1? NGW1bmZUSU6JRWK=
NB69 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHVO4I2UUN3ME2xMlA2KG6P NE\jcWRUSU6JRWK=
8505C MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwME[gcm0> MkPHV2FPT0WU
CAL-12T MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMEigcm0> MkXoV2FPT0WU
BHY NHTwVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrGTWM2OD1zLkG0JI5O NYHmU2h7W0GQR1XS
LB647-SCLC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPp[ZNEUUN3ME2xMlE5KG6P M4qyN3NCVkeHUh?=
CAL-62 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S5N2lEPTB;MT6yNkBvVQ>? M1jsdHNCVkeHUh?=
MEG-01 NH\1Z2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvLOItKSzVyPUGuNlchdk1? NH[zTpJUSU6JRWK=
MG-63 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwM{Ogcm0> MUHTRW5ITVJ?
SW620 NXrm[mFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rWd2lEPTB;MT6zOUBvVQ>? MY\TRW5ITVJ?
A388 NGrBPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfJRlZKSzVyPUGuN|Yhdk1? M3XaeXNCVkeHUh?=
BCPAP M4P5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHoTWoxUUN3ME2xMlQ2KG6P MljHV2FPT0WU
P30-OHK MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXJTWM2OD1zLkS2JI5O Mn;TV2FPT0WU
Ca9-22 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG3TG9KSzVyPUGuOVQhdk1? NUfwRohWW0GQR1XS
VMRC-RCZ NXjKTpVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzSOIVKSzVyPUGuOVQhdk1? MleyV2FPT0WU
LOXIMVI M2X2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwNjDuUS=> MlfqV2FPT0WU
L-540 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwNjDuUS=> NUDvRpFLW0GQR1XS
NTERA-S-cl-D1 NUC5d|FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XDbWlEPTB;MT62OEBvVQ>? MnXTV2FPT0WU
MFH-ino NXy3eYtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjBdpd{UUN3ME2xMlY3KG6P M3fsNnNCVkeHUh?=
Calu-6 NXXze4t6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW5TWM2OD1zLkezJI5O MWjTRW5ITVJ?
HEL M2DFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwN{mgcm0> M3XvcHNCVkeHUh?=
CAL-33 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwOEmgcm0> MlO0V2FPT0WU
HSC-3 NV;hcpJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwOUGgcm0> MkXlV2FPT0WU
KU812 M3TRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfDTWM2OD1zLkmxJI5O MkTZV2FPT0WU
EB2 M2SxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTQSJFKSzVyPUKuNFEhdk1? NULTNoJPW0GQR1XS
SR MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq5[nFKSzVyPUKuNVIhdk1? Mn;HV2FPT0WU
NCI-H2087 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWyTWM2OD1{LkG0JI5O MmrxV2FPT0WU
H4 M{Dmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO2TYtKSzVyPUKuNVghdk1? M{T6Z3NCVkeHUh?=
EW-1 NEjFRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwMkKgcm0> MnjsV2FPT0WU
MC-IXC NF[0dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vN[mlEPTB;Mj6yOkBvVQ>? MkXlV2FPT0WU
NCI-H727 NX;zTHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwNUGgcm0> MljQV2FPT0WU
MRK-nu-1 NXLBN3RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJwNUegcm0> NH7JZllUSU6JRWK=
COLO-668 NWHSRmpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnFTWM2OD1{Lk[2JI5O MYjTRW5ITVJ?
CGTH-W-1 M3K3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jXfGlEPTB;Mj63NkBvVQ>? MVHTRW5ITVJ?
CHP-212 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzYc2ZKSzVyPUKuO|Uhdk1? MV\TRW5ITVJ?
GI-1 M13KOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXKeo5KSzVyPUKuO|Yhdk1? M{O5dnNCVkeHUh?=
HCC1806 M3;zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\NTWFmUUN3ME2yMlkyKG6P M3v3eXNCVkeHUh?=
HLE MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:4TWM2OD1|IH7N Mlv5V2FPT0WU
HSC-2 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnF[G5KSzVyPUOuNFMhdk1? MmnVV2FPT0WU
DMS-273 NFfXNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwMEegcm0> M4ryeXNCVkeHUh?=
DU-4475 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe3W5pVUUN3ME2zMlE1KG6P NI\1U|VUSU6JRWK=
LXF-289 M2Wxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LMVGlEPTB;Mz6zNUBvVQ>? M2Ozd3NCVkeHUh?=
PANC-03-27 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm5TlNKSzVyPUOuOVEhdk1? MXzTRW5ITVJ?
GAMG MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm4dVN3UUN3ME2zMlc1KG6P NFrOc2pUSU6JRWK=
NCI-H522 NIrCSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzwWVBKSzVyPUSuN|Qhdk1? NFfISpVUSU6JRWK=
SW626 NVnkSXJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTRwNE[gcm0> M2XhT3NCVkeHUh?=
HT-144 NIHoW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P6NmlEPTB;ND65NkBvVQ>? NVvHfVczW0GQR1XS
MEL-HO NUe5ZWVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXZTWM2OD13LkG2JI5O Mn3GV2FPT0WU
BE-13 M1zHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvEbYZKSzVyPUWuNlEhdk1? NF7FZ45USU6JRWK=
VA-ES-BJ NGrrUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zQTGlEPTB;NT6yOkBvVQ>? NH7XWVRUSU6JRWK=
NCI-H441 NXPaOYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M376S2lEPTB;NT62JI5O NFvqTppUSU6JRWK=
KP-4 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwNkGgcm0> MWXTRW5ITVJ?
LoVo MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTVwN{Ggcm0> NXvLUHk6W0GQR1XS
HT-1080 M2jwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\qTWM2OD13LkizJI5O MXjTRW5ITVJ?
GB-1 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTVwOESgcm0> MWDTRW5ITVJ?
IA-LM Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTieXBKSzVyPUWuPVEhdk1? NV23XVUxW0GQR1XS
8-MG-BA M1fTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD6V2pKSzVyPUWuPVMhdk1? NGPEeWVUSU6JRWK=
SK-HEP-1 NYLpbndzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnxcGhKSzVyPU[uNVQhdk1? MmLLV2FPT0WU
697 NVjENFhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnuTWM2OD14LkK1JI5O M4niW3NCVkeHUh?=
KYSE-450 M2j5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfmUFlMUUN3ME22MlMzKG6P NYW0S2RPW0GQR1XS
HCC2998 M1fvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTZwM{Sgcm0> NH;5Uo9USU6JRWK=
HD-MY-Z M375NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrRTWM2OD14Lk[4JI5O MWTTRW5ITVJ?
OS-RC-2 M2XVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n6SmlEPTB;Nj62PEBvVQ>? M{LGVnNCVkeHUh?=
SF126 MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Sxb2lEPTB;Nz6wOUBvVQ>? MUHTRW5ITVJ?
Ca-Ski M{\1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjxU|FlUUN3ME23MlA6KG6P M3v1NnNCVkeHUh?=
NCI-H358 NVPGdJhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG4TG9KSzVyPUeuNVYhdk1? NWTzXY9oW0GQR1XS
J82 NIjNcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdwNEGgcm0> NV\qbJRmW0GQR1XS
NCI-H2342 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDWTWM2OD15Lk[zJI5O NWfUTGI2W0GQR1XS
OVCAR-8 M2\xbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf1SpJKSzVyPUeuPUBvVQ>? MoPDV2FPT0WU
TE-8 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRThibl2= NXvIfFM4W0GQR1XS
ETK-1 NXvQWYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\KTWM2OD16LkC4JI5O NF3wS4ZUSU6JRWK=
HAL-01 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CxfWlEPTB;OD6yJI5O M1qzcXNCVkeHUh?=
KYSE-150 NUfwc5NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LRcWlEPTB;OD60O{BvVQ>? NVfiT282W0GQR1XS
NCI-H810 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\nepVKSzVyPUiuOVYhdk1? M2XHSnNCVkeHUh?=
ONS-76 NXrXW5J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fkPWlEPTB;OD62PEBvVQ>? MnjCV2FPT0WU
NMC-G1 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLNTWM2OD16Lke2JI5O M1nsfXNCVkeHUh?=
C3A NWT6b|N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq2WHVKSzVyPUiuPFQhdk1? M3XuW3NCVkeHUh?=
PA-1 NXLSOI1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rxWWlEPTB;OD65PUBvVQ>? NULUV4VEW0GQR1XS
SH-4 M4[1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvS[oxKSzVyPUmuNFIhdk1? M17HXHNCVkeHUh?=
EFO-27 M170Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfId4x4UUN3ME25MlA2KG6P NIfMdYRUSU6JRWK=
CAPAN-1 M4X3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTlwMkOgcm0> MWPTRW5ITVJ?
DU-145 NG[5T5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO1[IoyUUN3ME25MlI6KG6P NGq2fXFUSU6JRWK=
A101D NHfKUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHroNVJKSzVyPUmuN|chdk1? NGXUUIVUSU6JRWK=
ST486 NXziZYoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTlwNEGgcm0> Ml;qV2FPT0WU
NCI-H1437 M3PuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTlwNEKgcm0> NYOxNY42W0GQR1XS
HGC-27 NEDqdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCxfJQxUUN3ME25MlYhdk1? MXXTRW5ITVJ?
8305C NYnNfppHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHBSHNMUUN3ME25MlY1KG6P MW\TRW5ITVJ?
OCUB-M Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrJTWM2OD1zMD6wN{BvVQ>? NIHYcllUSU6JRWK=
COLO-679 NFH1W5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvMcZNKSzVyPUGwMlA4KG6P MYDTRW5ITVJ?
Detroit562 NV7xNmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjLS2dKSzVyPUGwMlQzKG6P NXHoeJpmW0GQR1XS
A204 NV;hfXFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLFbZRKSzVyPUGxMlE3KG6P M2Xzd3NCVkeHUh?=
NCI-H1734 M1\Te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTvTW5KSzVyPUGxMlI6KG6P NVGwdFQ6W0GQR1XS
MC-CAR NHna[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHONGdKSzVyPUGxMlU5KG6P MWPTRW5ITVJ?
NCI-H2170 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljUTWM2OD1zMT65O{BvVQ>? MUTTRW5ITVJ?
NCI-SNU-5 M2PKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTYTWM2OD1zMj6xN{BvVQ>? MYfTRW5ITVJ?
HCE-T M4XwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF{LkSyJI5O MkHBV2FPT0WU
KYSE-180 NXn2V2Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF{LkixJI5O NWrMfYh3W0GQR1XS
C8166 M4P5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXTWINKSzVyPUGzMlA5KG6P M{HrcHNCVkeHUh?=
NCI-H460 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXsfmdKSzVyPUGzMlU1KG6P MXzTRW5ITVJ?
SNU-449 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF|Lke3JI5O NIDGZ2JUSU6JRWK=
MDA-MB-468 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jxb2lEPTB;MUSuNVIhdk1? M{HMeHNCVkeHUh?=
COR-L23 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WxfmlEPTB;MUSuNVMhdk1? NFPOeZBUSU6JRWK=
CTV-1 M2f6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF2LkG0JI5O NGfWd4xUSU6JRWK=
BL-41 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LtS2lEPTB;MUSuN|chdk1? MUnTRW5ITVJ?
IGR-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z2TGlEPTB;MUSuOFIhdk1? M13WcnNCVkeHUh?=
TK10 NYT3XI5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF2LkS5JI5O M4nGV3NCVkeHUh?=
REH NYjUbWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jmemlEPTB;MUSuOVEhdk1? MXvTRW5ITVJ?
LU-139 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrZWJhKSzVyPUG0MlU6KG6P M3;SZ3NCVkeHUh?=
KP-N-YS M1;BT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjWUlJuUUN3ME2xOE46PyCwTR?= NUn3TJZoW0GQR1XS
PANC-10-05 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f4OmlEPTB;MUWuN|ghdk1? MUPTRW5ITVJ?
HL-60 M{\J[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfNdlZKSzVyPUG1MlY6KG6P NFTzUYRUSU6JRWK=
T84 NXXYXY1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jEPGlEPTB;MUWuPVYhdk1? M3;CT3NCVkeHUh?=
RPMI-8226 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nyfGlEPTB;MU[uNFIhdk1? M4DwcnNCVkeHUh?=
UM-UC-3 NVT0ZYZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrVTY5KSzVyPUG2MlE3KG6P MU\TRW5ITVJ?
TE-10 NIXQTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWwPHJKSzVyPUG2MlIyKG6P M1z3[HNCVkeHUh?=
CAL-148 NUCyTXE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF5LkKzJI5O M3zqRnNCVkeHUh?=
BV-173 M3XrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi3RWdMUUN3ME2xO{4zPyCwTR?= NX;zdpBDW0GQR1XS
Calu-3 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF5LkK5JI5O NEnYVZhUSU6JRWK=
RPMI-2650 NV3XPGlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDO[2d[UUN3ME2xO{42QSCwTR?= MUHTRW5ITVJ?
MKN45 MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOzT3RLUUN3ME2xO{44OyCwTR?= NXvhVJZrW0GQR1XS
NUGC-3 NUHC[ox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\wSJoyUUN3ME2xPE4{PCCwTR?= MV3TRW5ITVJ?
NCI-H520 NV32OFJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv5eJlKSzVyPUG4Mlc4KG6P M1XVU3NCVkeHUh?=
CCRF-CEM NVvGW5pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHzOWVKSzVyPUG4Mlg2KG6P NGXabVdUSU6JRWK=
NCI-H2405 M1jROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;NOZhKSzVyPUG5MlEhdk1? Ml65V2FPT0WU
ES7 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzGTWM2OD1zOT63OkBvVQ>? NEKzXXhUSU6JRWK=
BPH-1 NYPa[pc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET4c3lKSzVyPUKwMlI5KG6P MkfyV2FPT0WU
SAS MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJyLkWgcm0> NWnoXoV5W0GQR1XS
HuCCT1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PtcWlEPTB;MkCuOVghdk1? MnT0V2FPT0WU
LOUCY NVTF[IdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqcoZKSzVyPUKwMlY3KG6P MULTRW5ITVJ?
NCI-H292 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfaNGtDUUN3ME2yNE44QSCwTR?= NXO0dpB3W0GQR1XS
G-361 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHhZZFoUUN3ME2yNU4xPyCwTR?= Mk\HV2FPT0WU
M059J NEfwclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4joZmlEPTB;MkGuNFghdk1? NIfSNJZUSU6JRWK=
NCI-H1651 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXaT2dPUUN3ME2yNU4yOSCwTR?= MVjTRW5ITVJ?
KALS-1 M1L3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjXV3lKSzVyPUKxMlM6KG6P NXnVSWZuW0GQR1XS
DJM-1 NWTQeIs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13OcGlEPTB;MkGuOVkhdk1? M1\TSHNCVkeHUh?=
AU565 NHzkeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJzLkizJI5O M{ewXHNCVkeHUh?=
HCC38 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGewXGlKSzVyPUKxMlk2KG6P NFjXTotUSU6JRWK=
U251 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrRTWM2OD1{Mj6yO{BvVQ>? NUHPVFMxW0GQR1XS
ABC-1 NH3sNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XyRWlEPTB;MkKuOlUhdk1? NF:xeIVUSU6JRWK=
SK-NEP-1 NIPE[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ZTWM2OD1{Mj65N{BvVQ>? NYjU[4lFW0GQR1XS
CESS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ|LkG5JI5O MWHTRW5ITVJ?
MIA-PaCa-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:xcmhGUUN3ME2yN{4{PiCwTR?= NXHmXHN2W0GQR1XS
SUP-T1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm0SHNKSzVyPUKzMlQ4KG6P NXuxWIxrW0GQR1XS
L-428 M2DUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwO3dKSzVyPUKzMlYzKG6P NHmy[4ZUSU6JRWK=
SW954 NWqwWVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ|Lk[4JI5O NVK4NGIxW0GQR1XS
HO-1-N-1 NYLPNlljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq2[HBKSzVyPUKzMlc4KG6P MUXTRW5ITVJ?
CHP-126 NUjXSmFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDLTWM2OD1{ND6xOEBvVQ>? MWfTRW5ITVJ?
HMV-II NH;CWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjmbmd[UUN3ME2yOE4{PCCwTR?= MY\TRW5ITVJ?
NB10 NGXDfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrzTWM2OD1{ND6zO{BvVQ>? Ml;KV2FPT0WU
A172 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\hfIlKSzVyPUK0MlcyKG6P MlnlV2FPT0WU
MONO-MAC-6 NHLzb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj6ZWtKSzVyPUK0Mlg1KG6P NYfBbmhYW0GQR1XS
NCI-H1650 NIfNR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3Z[2o{UUN3ME2yOU41KG6P MX;TRW5ITVJ?
NH-12 NG\6fnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DWRmlEPTB;MkWuOUBvVQ>? NYjPUIw2W0GQR1XS
ML-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnPZmxKSzVyPUK1Mlc1KG6P NUfJUndGW0GQR1XS
MZ2-MEL NV7LS|ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi2fld2UUN3ME2yOk4zOiCwTR?= Mnz6V2FPT0WU
COLO-684 NWjrXY9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTeVVUUUN3ME2yOk41OSCwTR?= NUflXWxbW0GQR1XS
HuP-T4 M2rIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ5LkOgcm0> NILBVFBUSU6JRWK=
SW837 M1vV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\McFlKSzVyPUK3MlYzKG6P NUDZe5l7W0GQR1XS
MDA-MB-231 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD1{Nz63PEBvVQ>? NF7Lc|NUSU6JRWK=
KYSE-140 M3XTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXLTWM2OD1{Nz65NUBvVQ>? NXXoO29KW0GQR1XS
NOMO-1 NInqWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnpXmV6UUN3ME2yPE43QCCwTR?= MkPjV2FPT0WU
GP5d NEDkUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ6LkeyJI5O NHHhUHdUSU6JRWK=
COR-L105 M2fRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[ySWlEPTB;MkmuOFIhdk1? NES5N4dUSU6JRWK=
LS-411N MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ7Lki4JI5O NHLHPHpUSU6JRWK=
NY Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNyLkG4JI5O NVnURo16W0GQR1XS
NCI-H2030 NYT6dWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNyLkS1JI5O NFfROlhUSU6JRWK=
CCF-STTG1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTvc5FpUUN3ME2zNU41OiCwTR?= MXTTRW5ITVJ?
NCI-H1703 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\JNWY6UUN3ME2zNU44QCCwTR?= NGW3Z29USU6JRWK=
TUR MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDtRWNKSzVyPUOyMlA{KG6P Mm\KV2FPT0WU
NOS-1 NUHnSo9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\UTWM2OD1|Mj60OEBvVQ>? M{LMVXNCVkeHUh?=
A2058 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTN{LkizJI5O M2fIdHNCVkeHUh?=
LCLC-103H NHf0Z5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHwUFRKSzVyPUOzMlI2KG6P MlvaV2FPT0WU
NCI-H510A NFnJN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN|LkK3JI5O NWTMV3c1W0GQR1XS
BC-1 NXjWZ2ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN|Lke3JI5O MlizV2FPT0WU
SK-CO-1 NEXNZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;KSppZUUN3ME2zOE4xOSCwTR?= NX:zc41[W0GQR1XS
A673 NF;GTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTN2LkG3JI5O NYrDW|lpW0GQR1XS
VM-CUB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TUTmlEPTB;M{SuOlkhdk1? Mn:2V2FPT0WU
HH M1mybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN3LkC2JI5O M{fnUnNCVkeHUh?=
CAL-27 M{LFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[wVXRKSzVyPUO1MlE3KG6P NF\w[2xUSU6JRWK=
NEC8 M3eyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q4VmlEPTB;M{WuN|chdk1? MmTBV2FPT0WU
BxPC-3 NH;RUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDQTWM2OD1|Nj65NUBvVQ>? Mlm1V2FPT0WU
SNB75 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\aXWtyUUN3ME2zO{4zPCCwTR?= MUDTRW5ITVJ?
NB13 NFjGNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7iW5Q4UUN3ME2zPE4zOyCwTR?= M4KycHNCVkeHUh?=
SK-OV-3 M3zDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvpdFJKSzVyPUO4Mlc1KG6P M2fOOXNCVkeHUh?=
ME-180 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2z[nJKSzVyPUO4Mlghdk1? MVfTRW5ITVJ?
JiyoyeP-2003 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXXTWM2OD1|OT6zPEBvVQ>? NYGxcYNvW0GQR1XS
LU-134-A MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W0TGlEPTB;NECuNFIhdk1? MkXqV2FPT0WU
LS-123 NGrrWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDYdJZiUUN3ME20NE4zQCCwTR?= NWDBSZA6W0GQR1XS
COLO-800 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rZfWlEPTB;NECuOVYhdk1? NGHsRWZUSU6JRWK=
LB831-BLC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXiTWM2OD12MT64OUBvVQ>? MVTTRW5ITVJ?
NCI-H747 NVfmXWlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjuZm9DUUN3ME20Nk4zQCCwTR?= M1HDb3NCVkeHUh?=
MZ7-mel MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP1bIh5UUN3ME20Nk43PiCwTR?= Mly1V2FPT0WU
GT3TKB NEPy[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqwTWM2OD12Mj63NkBvVQ>? MXnTRW5ITVJ?
MOLT-16 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTGeo9lUUN3ME20N{4xPSCwTR?= M3fMZnNCVkeHUh?=
23132-87 NI\iVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ryPWlEPTB;NEOuNFUhdk1? NXj5NHhPW0GQR1XS
PF-382 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR2LkKyJI5O MVnTRW5ITVJ?
ES3 NHW1UldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPKPYFKSzVyPUS0MlYhdk1? NGDiU|lUSU6JRWK=
SW756 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LQVWlEPTB;NEWuNVQhdk1? Mk\pV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID